A Randomized, Double-blind, Placebo-controlled Study on the Anti-Glycation Effect of Food Containing Pomegranate Extract

A Randomized, Double-blind, Placebo-controlled Study on the Anti-Glycation Effect of Food Containing Pomegranate Extract - Anti-Glycation Effect of Food Containing Pomegranate Extract

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015025

Enrollment

Registered

2014-09-03

Start date

2014-08-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

No (Subjects with high amount of skin AGEs accumulation)

Interventions

Capsule containing 100mg of pomegranate extract, 1 per serving per day Capsule not containing pomegranate extract, 1 per serving per day

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: (1)(Healthy) post-menopausal females aged 50 to 65 years old. (2)Subjects whose skin AGEs accumulation determined by AGEReader is more than 2.0. (3)Subjects who prefer carbohydrates or sweets. (4)Subjects whose waist circumference is more than 90 cm. (5)Subjects giving written informed consent.

Exclusion criteria

Exclusion criteria: (1)Subjects who use oral medication affecting blood sugar. (2)Subjects who constantly use supplements and/or functional foods affecting blood sugar. (3)Smoker. (4)Subjects who have allergic reaction to pomegranate. (5)Subjects who can't promise not to drink four or more times a week and more than 2 cups in terms of sake in a day. (6)Subjects who daily average sleep time is less than 6 hours approximately. (7)Subjects who are during treatment and/or medication with lifestyle-related diseases related to glycation. (8)Subjects who are suffering from a disease that requires urgent treatment or are having severe complications. (9)Subjects who have under treatment or a history of drug addiction and/or alcoholism. (10)Subjects who are planned to participate in other clinical study. (11)Subjects who are judged as unsuitable for the study by the investigator for other reason.

Design outcomes

Primary

Measure	Time frame
HbA1c Glycoalbumin (carboxymethyl)lysine (CML) 3-Deoxyglucosone Pentosidine Skin AGEs Skin elasticity Color difference of skin Analysis of stains, wrinkles, pores, skin color, hidden stains using VISIA Horny layer AGEs	—

Secondary

Measure	Time frame
Fasting Plasma Glucose Insulin Anti-aging QOL common questionnaire test	—

Countries

Japan

Contacts

Public ContactYoshika Komori

KSO Corporation Sales department

yoshi@kso.co.jp03-3452-7733

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026